REG - Faron Pharma. Oy - Exercise of options

Faron Pharmaceuticals OyAnnouncement

27/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231027:nRSa4718Ra&default-theme=true

RNS Number : 4718R  Faron Pharmaceuticals Oy  27 October 2023

Faron Pharmaceuticals Ltd.

 

("Faron")

 

Exercise of options

Issue of equity

 

Company announcement, October 27, 2023 at 7:15 a.m. BST / 9:15 a.m. EEST

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical- stage biopharmaceutical company focused on tackling
cancers via novel immunotherapies, announces that it has received
notifications from option holders to exercise 2015B options over 22,306 in the
Company at an exercise price of EUR 2.90 (approx. GBP 2.48) per share and
2015D options over 25,873 shares in the Company at an exercise price of EUR
1.09 (approx. GBP 0.93) per share under the Company's 2015 Option Plan ("New
Ordinary Shares"). The terms and conditions of the 2015 Option Plan are
available on the Company's website at
https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf
(https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf)
.

 

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to
admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth
Market, respectively. Admission of the New Ordinary Shares is expected to
occur on or around October 30, 2023 following issue and registration of the
New Ordinary Shares on or around October 31, 2023 ("Registration"). The New
Ordinary Shares will rank pari passu with existing ordinary shares.

 

Faron's enlarged issued number of shares immediately following Registration
will be 68,786,699 ordinary shares with voting rights attached. The Company
has no shares in treasury; therefore upon, and subject to, Registration, the
total number of voting rights in Faron will be 68,786,699. This figure may be
used by shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in, or a change
to their interest in, the issued shares and votes of the Company.

 

For more information please contact:

 

Investor Contact

LifeSci Advisors 

Daniel Ferry 

Managing Director 

daniel@lifesciadvisors.com 

+1 (617) 430-7576 

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About Faron Pharmaceuticals Ltd. 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials
as a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.faron.com%2F&data=05%7C01%7C%7Ca4ae0afa96854c5c5f2a08db771ae20d%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638234729855975666%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FNadoN9wXIGZtfCkFVuLSTXPpNg3%2BBXoRfIQaIPce6k%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBQLLLXBLEFBZ